Last updated on April 2019

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Brief description of study

To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia

Clinical Study Identifier: NCT03121586

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.